CAPRICOR THERAPEUTICS INC

Capricor Therapeutics pursues breakthrough therapies for Duchenne muscular dystrophy, blending clinical‑stage innovation with a transparent, patient‑focused strategy.

Capricor Therapeutics to release Q2 2026 earnings, spotlighting Deramiocel for DMD and its StealthX platform—click to see investor call details and market insights.

Capricor Therapeutics: Nasdaq‑listed biotech targeting Duchenne Muscular Dystrophy and other rare disorders with innovative therapies. Discover its clinical progress, market dynamics, and global impact.

Capricor Therapeutics faces multiple securities‑fraud class‑action lawsuits, sparking investor alerts and potential volatility in its stock price.

Capricor Therapeutics: Nasdaq biotech focused on Duchenne Muscular Dystrophy, navigating market volatility while advancing promising biological therapies for rare disorders.

Capricor Therapeutics rebounds after data‑manipulation claims, with new DMD trial results boosting investor confidence and stock value.

Capricor Therapeutics faces market volatility as the FDA advisory committee reviews its DMD drug Deramiocel; investors await outcomes and new clinical data.

Capricor Therapeutics Q1 2026: flat revenue, slight EPS decline, yet promising FDA review and scale‑up plans for its DMD therapy, driving analyst optimism.

Capricor Therapeutics gears up for a landmark U.S. review of its Deramiocel therapy for Duchenne muscular dystrophy, a breakthrough that could reshape rare disease treatment and boost investor confidence.

Capricor Therapeutics, a clinical‑stage biotech focused on Duchenne muscular dystrophy, drew a high‑profile stake from Tang Capital, boosting investor confidence and highlighting its promising yet volatile stock prospects.